Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.

Similar presentations


Presentation on theme: "Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio."— Presentation transcript:

1 Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio Olivieri, Michele Cimminiello, Paolo Corradini, Nicola Mordini, Roberta Fedele, Carmine Selleri, Francesco Onida, Francesca Patriarca, Enzo Pavone, Silvia Svegliati, Armando Gabrielli, Paola Bresciani, Roberta Nuccorini, Sara Pascale, Sabrina Coluzzi, Fabrizio Pane, Antonella Poloni, Jacopo Olivieri, Pietro Leoni, and Andrea Bacigalupo Blood Volume 122(25): December 12, 2013 ©2013 by American Society of Hematology

2 Individual organ severity scoring within global severity categories. Attilio Olivieri et al. Blood 2013;122: ©2013 by American Society of Hematology

3 Survival outcomes. Attilio Olivieri et al. Blood 2013;122: ©2013 by American Society of Hematology

4 Thirty-six of the 39 patients receiving imatinib were alive at 6 months and were included in a landmark analysis for overall survival (OS) according to response status at 6 months. Attilio Olivieri et al. Blood 2013;122: ©2013 by American Society of Hematology

5 Mean change in the ROS stimulatory index (ROI) of cGVHD Igs before and after imatinib treatment according to response status (Center Response). Attilio Olivieri et al. Blood 2013;122: ©2013 by American Society of Hematology


Download ppt "Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio."

Similar presentations


Ads by Google